Skip to content
2000
Volume 18, Issue 1
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Background: Lumacaftor/Ivacaftor (LUM/IVA) is an approved combination therapy for cystic fibrosis (CF) patients homozygous for F508del. Objective: This study aimed to detect changes in liver stiffness measurement (LSM) in patients under this treatment. Methods: The study population consisted of CF patients homozygous for F508del, 6 to 11 years old, who had been treated for six months with LUM/IVA. Shear wave elastography (SWE) was performed in all of them, before and 6 months after the commencement of treatment. Results: Thirty-one patients were included in the study. LSM values after treatment were significantly higher than the values before treatment (medians and interquartile ranges of LSM values before and after treatment: 5.6, 5.3-6.3 kPa and, 6.4, 6.0-7.6 kPa, respectively, p<0.001). Conclusion: SWE can detect early changes in LSM in some CF patients treated with LUM/IVA.

Loading

Article metrics loading...

/content/journals/cds/10.2174/1574886317666220513105114
2023-02-01
2025-08-27
Loading full text...

Full text loading...

/content/journals/cds/10.2174/1574886317666220513105114
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test